FOLH1 and prostate cancer: 177Lu-prostate-specific membrane antigen-617 (177Lu-PSMA-617) is a radioligand therapy that targets prostate-specific membrane antigen (PSMA), a receptor highly expressed on prostate cancer cells (1).